ABOUT
We tackle discovery challenges — such as identifying the unique pathways that regulate immune cytotoxicity in specific cancers — using our proprietary Intelligent Design™ technology. Powered by AI-driven bioinformatics and guided by our team of scientists, engineers, and clinicians, Feromics uncovers actionable biology that drives therapeutic innovation.
Approach
PRECISION. PERSONALIZATION. INNOVATION.
At Feromics, we combine Intelligent Design™ technology with deep biological insight to develop highly effective immunotherapy treatments. Our approach begins with creating proprietary libraries of interacting disease and immune cells, categorized by functional phenotypes such as cancer cell-killing.
By integrating AI and deep learning, we uncover novel, therapeutically relevant, function-specific pathways that inform our solutions across multiple areas — including the design and optimization of CAR-T and CAR-Treg constructs to enhance efficacy and safety.
Donor selection for allogeneic immunotherapies ensures cells provide high therapeutic efficacy and patient compatibility. Preclinical and clinical development is derisked, enabling streamlined translation from research to clinic and personalized treatment based on each patient’s unique immune profile.
Partnerships
BETTER TOGETHER
Feromics empowers discovery through functional immunomics. Our Intelligent Design™ technology and mission-focused team help partners uncover key immune cell pathways and expand immunotherapy pipelines with actionable insights.
Grants
SUPPORTING OUR RESEARCH
Feromics was awarded a $4.1M three-year contract from the Advanced Research Projects Agency for Health (ARPA-H) to develop a precision medicine technology that improves patient treatment selection in cancer immunotherapy.
Under Contract No. 75N91024C00036, ARPA-H — part of the Department of Health and Human Services — supports Feromics’ cutting-edge biomedical and health innovations.
OUR STORY
Feromics began at the laboratory of Professor Tania Konry at Northeastern University, where engineers, biologists, and computer scientists developed a novel biotechnology for single-cell assays in cancer and autoimmune disease.
Since 2013, this work has produced over 52 scientific papers and patents, alongside collaborations with leading pharmaceutical companies. In 2022, Dr. Shai Schubert joined Dr. Konry as CEO to co-found Feromics, bringing the vision and leadership that drives our mission: developing innovative treatments that deliver life-changing outcomes. The scientific foundation of Feromic's Intelligent Design™ platform’s has been independently validated by the U.S. government — and Feromics was awarded a $4.1 million grant from ARPA-H, the Advanced Research Projects Agency for Health, in recognition of its potential to transform cancer immunotherapy.
OUR PEOPLE
Pioneering transformative breakthroughs that redefine discovery.
MISSION
Feromics is the first and only AI-driven functional immunomics platform built from the biology up. By isolating disease-specific immune cells and uncovering the functional pathways that drive disease and therapeutic response, we accelerate the development of new treatments for cancer and autoimmune diseases.